S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
NYSE:BTX

Brooklyn ImmunoTherapeutics (BTX) Stock Forecast, Price & News

$2.08
+0.02 (+0.97%)
(As of 09/21/2023 ET)
Compare
Today's Range
$2.00
$2.18
50-Day Range
$2.05
$2.96
52-Week Range
$0.17
$10.10
Volume
4,443 shs
Average Volume
515,543 shs
Market Capitalization
$122.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BTX stock logo

About Brooklyn ImmunoTherapeutics (NYSE:BTX) Stock

Eterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.

BTX Price History

BTX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Brooklyn Hospital Center
Brooklyn Technical High School
Brooklyn Preparatory High School
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Brooklyn ImmunoTherapeutics Announces Board Changes
See More Headlines
Receive BTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Television Broadcasting
Sub-Industry
N/A
CIK
N/A
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$122.36 million
Optionable
Optionable
Beta
4.61
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Matthew Angel
    President, Chief Executive Officer & Director
  • Andrew C. Jackson
    Chief Financial Officer
  • Roger Sidhu
    Chief Medical Officer
  • Jay Sial
    Chief Administrative Officer
  • Sandra Gurrola
    Principal Accounting Officer & VP-Finance













BTX Stock - Frequently Asked Questions

How have BTX shares performed in 2023?

Brooklyn ImmunoTherapeutics' stock was trading at $3.22 at the beginning of 2023. Since then, BTX stock has decreased by 35.4% and is now trading at $2.08.
View the best growth stocks for 2023 here
.

What is Brooklyn ImmunoTherapeutics' stock symbol?

Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "BTX."

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brooklyn ImmunoTherapeutics' stock price today?

One share of BTX stock can currently be purchased for approximately $2.08.

How much money does Brooklyn ImmunoTherapeutics make?

Brooklyn ImmunoTherapeutics (NYSE:BTX) has a market capitalization of $122.36 million.

How can I contact Brooklyn ImmunoTherapeutics?

The company can be reached via phone at (212) 582-1199.

This page (NYSE:BTX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -